William Blair Comments on Harrow's Q3 Earnings (NASDAQ:HROW)

Key Points

• William Blair analysts have lowered their Q3 2025 EPS estimate for Harrow, Inc. from $0.13 to $0.07 per share, while maintaining an "Outperform" rating on the stock.
• The consensus estimate for Harrow's full-year earnings currently stands at ($0.53) per share, highlighting ongoing financial challenges for the company.
• Institutional ownership is significant, with 72.76% of shares held by hedge funds and other institutional investors, indicating strong institutional interest in the stock.

Harrow, Inc. (NASDAQ:HROW - Free Report) - Analysts at William Blair decreased their Q3 2025 earnings per share (EPS) estimates for Harrow in a report issued on Tuesday, September 9th. William Blair analyst L. Hanbury-Brown now expects that the company will post earnings of $0.07 per share for the quarter, down from their previous estimate of $0.13. William Blair has a "Outperform" rating on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. William Blair also issued estimates for Harrow's Q4 2025 earnings at $0.36 EPS, Q1 2026 earnings at ($0.27) EPS, Q2 2026 earnings at $0.44 EPS, Q3 2026 earnings at $0.40 EPS and Q4 2026 earnings at $0.76 EPS.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.01 by $0.23. Harrow had a negative net margin of 4.49% and a negative return on equity of 2.18%. The firm had revenue of $63.74 million for the quarter, compared to the consensus estimate of $64.23 million. Harrow has set its FY 2025 guidance at EPS.

Several other equities research analysts have also issued reports on the company. Zacks Research lowered Harrow from a "strong-buy" rating to a "hold" rating in a report on Friday. BTIG Research raised their price objective on shares of Harrow from $62.00 to $63.00 and gave the company a "buy" rating in a research report on Thursday, August 14th. Cantor Fitzgerald assumed coverage on shares of Harrow in a research report on Friday, July 11th. They set an "overweight" rating and a $76.00 price objective on the stock. Finally, HC Wainwright raised their price objective on shares of Harrow from $60.00 to $64.00 and gave the company a "buy" rating in a research report on Wednesday, August 13th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $64.67.

Harrow Stock Up 1.2%

Shares of Harrow stock traded up $0.53 on Thursday, hitting $43.35. 484,129 shares of the company traded hands, compared to its average volume of 485,317. The company has a quick ratio of 0.58, a current ratio of 0.62 and a debt-to-equity ratio of 0.78. Harrow has a 12-month low of $20.85 and a 12-month high of $59.23. The company has a 50-day moving average price of $36.35 and a 200 day moving average price of $30.14. The company has a market cap of $1.60 billion, a PE ratio of -173.12 and a beta of 0.33.

Hedge Funds Weigh In On Harrow

A number of institutional investors and hedge funds have recently bought and sold shares of HROW. Northern Trust Corp increased its position in Harrow by 7.5% during the fourth quarter. Northern Trust Corp now owns 319,084 shares of the company's stock worth $10,705,000 after acquiring an additional 22,266 shares during the period. Deutsche Bank AG increased its holdings in Harrow by 100.9% in the 4th quarter. Deutsche Bank AG now owns 108,064 shares of the company's stock valued at $3,626,000 after buying an additional 54,273 shares during the period. Graham Capital Management L.P. bought a new stake in Harrow in the 4th quarter valued at $392,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Harrow by 3.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,356 shares of the company's stock valued at $582,000 after buying an additional 585 shares during the period. Finally, ProShare Advisors LLC increased its holdings in Harrow by 30.8% in the 4th quarter. ProShare Advisors LLC now owns 10,289 shares of the company's stock valued at $345,000 after buying an additional 2,421 shares during the period. Institutional investors own 72.76% of the company's stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.